Trial · NCT01544283
Pain Patch Versus Injections in the Treatment of Pain Associated With Shoulder Impingement Syndrome
NCT01544283, Phase 2, Unknown, Injury Care Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pain Patch Versus Injections in the Treatment of Pain Associated With Shoulder Impingement Syndrome. Trials, record NCT01544283. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01544283
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pain Patch Versus Injections in the Treatment of Pain Associated With Shoulder Impingement Syndrome
- NCT number
- NCT01544283
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Injury Care Medical Center
- Conditions
- Shoulder Pain
- Interventions
- Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch, Triamcinolone Acetonide
- First posted
- 2012-03-05
- Last updated
- 2012-03-06
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain Intensity | 6 weeks | Average pain and worst pain over past 24 hours will be measured. |
| Secondary | Patient Global Assessment of Treatment Satisfaction | 6 weeks | |
| Secondary | Patient Global Impression of Change | 6 weeks | |
| Secondary | Pain Interference | 6 weeks | Pain interference as it relates to general activity, normal work, and sleep will be measured at each visit. |
| Secondary | Patch Site Evaluation for Erythema | 6 weeks | site patch is applied will be assessed for erythema and patch site reactions |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01544283
GET https://conductscience.org/api/trials/v1/NCT01544283/registered